Neuroprotection trials in Parkinson's disease: systematic review

Movement Disorders : Official Journal of the Movement Disorder Society
Robert G HartJohn R Marler

Abstract

Treatments to slow the progression are a major unmet need in Parkinson's disease. Detailed assessment of randomized trials testing putative neuroprotective drugs was undertaken to inform the design, reporting, and interpretation of future studies. This study is a systematic review of trials testing neuroprotective drugs. Data were extracted independently by two coauthors. Fifteen completed, published trials involving 4,087 participants tested 13 different drugs in 18 double-blind comparisons with placebo. Seven comparisons involving 2,000 subjects assessed MAO-B inhibitors. The primary outcome was change in the Unified Parkinson's Disease Rating Scale score in eight trials and time to need for dopaminergic therapy in seven. Mean participant age was 62 years, 35% were women, the interval from diagnosis to entry averaged 11 months, and the number of participants averaged 272 (largest = 806). Follow-up averaged <16 months in all but two trials. Detailed randomization methods and success of double-blinding were reported in 20% and 13%, respectively. Based on the investigators' conclusions, six trials were interpreted as consistent with a neuroprotective effect, three as negative, and five as either confounded or not meeting criteri...Continue Reading

References

Nov 1, 1995·Annals of Neurology·C W OlanowJ Esterlitz
Jan 21, 1993·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Aug 24, 1999·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J P LarsenJ E Erdal
Mar 26, 2002·Brain : a Journal of Neurology·Andrew J HughesAndrew J Lees
Apr 3, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN Parkinson Study Group
Jun 1, 2002·Parkinsonism & Related Disorders·J Jankovic, C Hunter
Oct 11, 2002·Archives of Neurology·Clifford W ShultsUNKNOWN Parkinson Study Group
May 2, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Irene LitvanUNKNOWN Movement Disorders Society Scientific Issues Committee
Jun 20, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·UNKNOWN Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease
Jul 3, 2003·Annals of Neurology·Alan L WhoneUNKNOWN REAL-PET Study Group
Apr 21, 2004·Archives of Neurology·UNKNOWN Parkinson Study Group
Oct 13, 2004·Neurology·Peter A LeWitt
Dec 8, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Katherine GrossetUNKNOWN Parkinson's Disease Research Group of the United Kingdom
Dec 14, 2004·The New England Journal of Medicine·Stanley FahnUNKNOWN Parkinson Study Group
Jan 26, 2005·Neurology·B RavinaR Holloway
Jan 26, 2005·Annals of Neurology·Jordan J ElmUNKNOWN NET-PD Investigators
Oct 12, 2005·Neurology·V L Marshall, Donald G Grosset
Feb 21, 2006·Annals of Neurology·Anthony H V Schapira, Jose Obeso
Mar 15, 2006·Neurology·B C TilleyUNKNOWN NET-PD Investigators
Apr 21, 2006·Journal of Pharmacokinetics and Pharmacodynamics·Nicholas H G HolfordUNKNOWN Parkinson Study Group
May 24, 2006·Neurology·Robert A Hauser, Theresa A Zesiewicz
May 24, 2006·Neurology·Andrew Siderowf, Matthew Stern
Nov 23, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzNancy LaPelle
Jan 4, 2007·Neurology·UNKNOWN NINDS NET-PD Investigators
Sep 21, 2007·Neurology·UNKNOWN Parkinson Study Group PRECEPT Investigators
May 14, 2008·Neurology·Heiko Braak, Kelly Del Tredici
Jun 11, 2008·Archives of Neurology·William J Weiner

❮ Previous
Next ❯

Citations

May 13, 2011·Journal of Neurology·Anthony H V Schapira
Jun 27, 2012·Journal of Neural Transmission·Sagar KansaraWeidong Le
May 15, 2012·Current Neurology and Neuroscience Reports·Xiqun ChenMichael A Schwarzschild
Jan 12, 2012·Neuroscience Bulletin·Ruiping Xia, Zhi-Hong Mao
May 25, 2010·Nature Medicine·Jose A ObesoGlenda Halliday
May 19, 2010·Nature Reviews. Neurology·Anthony H V Schapira, Eduardo Tolosa
Nov 9, 2011·The Neurologist·Isabel Ybot-GorrinFélix Javier Jiménez-Jiménez
Feb 3, 2011·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H V Schapira
Mar 15, 2013·Neuropsychiatric Disease and Treatment·David J Pedrosa, Lars Timmermann
Aug 5, 2011·Drugs & Aging·Claire Henchcliffe, W Lawrence Severt
Nov 22, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Haydeh Payami, Stewart A Factor
Nov 5, 2016·NPJ Parkinson's Disease·Umar YazdaniDwight C German
Nov 5, 2013·Parkinsonism & Related Disorders·Chava PeretzNir Giladi
Feb 4, 2010·Parkinsonism & Related Disorders·Anthony H V Schapira
Jul 1, 2015·Contemporary Clinical Trials·Bruce Levin
Oct 21, 2017·International Journal of Molecular Sciences·Napoleon TorresAlim Louis Benabid
Feb 14, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Scott J JohnsonAndrew D Siderowf
Feb 26, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Stacey L KowalAnjali Jain
Jun 3, 2010·Annals of Neurology·Hsiao-Chun ChengRobert E Burke
Jun 15, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Anthony H V SchapiraKenneth Marek
Jul 11, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Luc J W EversTom M Heskes
Jul 10, 2012·Current Opinion in Neurology·Werner PoeweJoseph Jankovic
Apr 1, 2020·Annals of Internal Medicine·UNKNOWN Parkinson Study Group STEADY-PD III Investigators
Jun 1, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Olivier RascolWerner Poewe
Jun 21, 2014·Current Opinion in Neurology·Rajesh Pahwa, Kelly E Lyons
Apr 6, 2019·Movement Disorders Clinical Practice·Ruth B SchneiderMichael P McDermott
Jun 8, 2017·Annals of Clinical and Translational Neurology·Kevin M BiglanUNKNOWN Parkinson Study Group STEADY‐PD III Investigators
Apr 20, 2017·Frontiers in Neuroscience·Yuho OkitaDean L Pountney

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
Anthony H SchapiraKenneth Marek
The New England Journal of Medicine
C Warren OlanowADAGIO Study Investigators
Nature Reviews. Drug Discovery
Anthony H SchapiraGiora Davidai
© 2021 Meta ULC. All rights reserved